We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HUTCHMED

News List

HUTCHMED and AstraZeneca Begin Phase II Trial of ORPATHYS® in Gastric Cancer americanpharmaceuticalreview
July 29, 2021
HUTCHMED and AstraZeneca PLC have initiated a Phase II study of ORPATHYS® (savolitinib), an oral, potent, and highly selective small-molecule inhibitor of MET, a receptor tyrosine kinase, in patients with advanced or metastatic MET amplified gastric ...
HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda(R) in China) for Advanced Pancreatic Neuroendocrine Tumors prnasia
June 22, 2021
HUTCHMED (China) Limited announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China ("NMPA") for the treatment of advanced pancreatic neuroendocrine tumors ("pNETs").